Eli Lilly and Company $LLY Shares Acquired by Profund Advisors LLC

Profund Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 11.6% in the third quarter, HoldingsChannel.com reports. The firm owned 10,648 shares of the company’s stock after purchasing an additional 1,110 shares during the quarter. Profund Advisors LLC’s holdings in Eli Lilly and Company were worth $12,321,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ProShare Advisors LLC increased its holdings in shares of Eli Lilly and Company by 4.0% during the third quarter. ProShare Advisors LLC now owns 134,385 shares of the company’s stock worth $155,494,000 after purchasing an additional 5,181 shares during the period. Vise Technologies Inc. raised its position in shares of Eli Lilly and Company by 19.9% in the third quarter. Vise Technologies Inc. now owns 41,180 shares of the company’s stock valued at $47,648,000 after buying an additional 6,827 shares in the last quarter. Investment Partners LTD. boosted its stake in shares of Eli Lilly and Company by 28.6% in the third quarter. Investment Partners LTD. now owns 7,314 shares of the company’s stock valued at $8,463,000 after buying an additional 1,627 shares during the period. Intrua Financial LLC boosted its stake in shares of Eli Lilly and Company by 0.6% in the third quarter. Intrua Financial LLC now owns 2,257 shares of the company’s stock valued at $2,612,000 after buying an additional 13 shares during the period. Finally, BNB Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 4.1% in the third quarter. BNB Wealth Management LLC now owns 641 shares of the company’s stock valued at $741,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of recent research reports. BMO Capital Markets restated an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Argus upped their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday. Truist Financial reiterated a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday. Morgan Stanley increased their target price on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Guggenheim raised their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Down 0.4%

NYSE LLY opened at $1,412.06 on Tuesday. The stock has a 50-day moving average of $1,200.81 and a 200-day moving average of $1,094.25. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,449.68. The firm has a market cap of $1.33 trillion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same period last year, the company posted $7.02 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.